Education
About Us
Working with TipRanks
Follow Us
JAMES V CARUSO Insider Profile
4 Followers
JAMES V CARUSO, CEO, Director at Cellectar Biosciences, holds 11.64K shares in Cellectar Biosciences (Ticker: CLRB). Most recently, JAMES V CARUSO Bought $10,000 shares of Cellectar Biosciences on Jul 03, 2025 for an estimated value of 49.90K.
JAMES V CARUSO Cellectar Biosciences (CLRB)CEO, Director
Cellectar Biosciences (CLRB)
CEO, Director
Ranked #97,216 out of 102,830 Corporate Insiders
Profitable Transactions
2 out of 9 Profitable Transactions
Average Return
-41.10%
Average return per transaction
Time Frame
Compare to
Insider Roles
CEO, Director
Roles that JAMES V CARUSO holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Jun 08, 2020 - Jun 08, 2021
Return:+28.80%
The most profitable trade made by JAMES V CARUSO
JAMES V CARUSO's Trading History
List of latest transactions for each holding click on a transaction to see JAMES V CARUSO's performance on stock
You May Also Like
JAMES V CARUSO insider profile FAQ
What is the percentage of profitable transactions made by JAMES V CARUSO?
The percentage of profitable transactions made by JAMES V CARUSO is 22%.
What is the average return per transaction made by JAMES V CARUSO?
The average return per transaction made by JAMES V CARUSO is -41.10%.
What stocks does JAMES V CARUSO hold?
JAMES V CARUSO holds: CLRB stocks.
What was JAMES V CARUSO’s latest transaction?
JAMES V CARUSO latest transaction was an Informative Buy of $49.90K.
What was JAMES V CARUSO's most profitable transaction?
JAMES V CARUSO’s most profitable transaction was an Informative Buy of CLRB stock on June 8, 2020. The return on the trade was 28.80%.
What is JAMES V CARUSO's role in Cellectar Biosciences?
JAMES V CARUSO's role in Cellectar Biosciences is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.